1. Home
  2. BMEA

as 07-23-2024 2:30pm EST

$
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Stocks

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

Biomea Fusion Inc is a preclinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of irreversible small molecule drugs to treat patients with genetically defined cancers. The company's product candidate, BMF-219, is designed to be an orally bioavailable, potent and selective irreversible inhibitor of menin, an important transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers.

Founded: 2017 Country:
United States
United States
Employees: N/A City: REDWOOD CITY
Market Cap: 189.1M IPO Year: 2021
Target Price: $26.63 AVG Volume (30 days): 1.1M
Analyst Decision: Buy Number of Analysts: 10
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -3.57 EPS Growth: N/A
52 Week Low/High: $3.61 - $23.07 Next Earning Date: 07-29-2024
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): N/A

BMEA Daily Stock ML Predictions

Share on Social Networks: